As one of the best developmental therapeutics programs in the country, our clinical pharmacologists conduct more clinical trials than any pediatric cancer center in the nation and are leaders in the development of new chemotherapy treatments for pediatric cancer.
Newly diagnosed diffuse pontine gliomas
ABT-888 inhibits the formation of poly (ADP-ribose) polymers. When the DNA is damaged by cytotoxic agents, ABT-888 inhibits the repair of the DNA and increases antitumor efficacy when added to DNA-damaging therapies such as temozolomide. ABT-888 will be given twice daily Monday through Friday for 6-7 weeks concurrently with daily radiation therapy. Following a 2-3 week rest period, patients will continue with maintenance therapy starting week 11 which consists of 5 consecutive days of twice daily ABT-888 plus once daily temozolomide. This may be repeated every 28 days for a maximum of 10 courses. In a study of ABT-888 and temozolomide in children with recurrent CNS tumors as well as adult clinical trials, the most commonly reported side effects were neutropenia and thrombocytopenia.
- Patients must be ≤ 21 years of age.
- Patients must have a newly diagnosed diffuse intrinsic pontine glioma.
- Patients must be able to swallow oral medications.
- Patients must not have received any prior therapy other than steroids.
- Patients must have adequate organ function, including bone marrow, renal, and hepatic.
- Patients with uncontrolled seizures are not eligible.
For the current status and more detailed eligibility criteria of these clinical studies and protocols, referring physicians and families may call the Developmental Therapeutics Program directly at (832) 824-4266 at any time. Kate Mazur, a pediatric nurse practitioner for the Developmental Therapeutics Program, will answer any questions or concerns you may have. You may need to leave a voice mail, and she will return your call as soon as possible. She may also be reached by email at email@example.com.